Anti-CAC1A/ CACNA1A/ APCA monoclonal antibody
Anti-CAC1A/ CACNA1A/ APCA antibody for FACS & in-vivo assay
Go to CACNA1A/CACNA1A products collection >>
(antibodies, antigen, VLP, mRNA, ORF viral vector, etc)
Product information
Catalog No. | Product Name | Species Reactivity |
---|---|---|
GM-Tg-hg-T34949-Ab-1/ GM-Tg-hg-T34949-Ab-2 | Anti-Human CACNA1A monoclonal antibody | Human |
GM-Tg-rg-T34949-Ab-1/ GM-Tg-rg-T34949-Ab-2 | Anti-Rat CACNA1A monoclonal antibody | Rat |
GM-Tg-mg-T34949-Ab-1/ GM-Tg-mg-T34949-Ab-2 | Anti-Mouse CACNA1A monoclonal antibody | Mouse |
GM-Tg-cynog-T34949-Ab-1/ GM-Tg-cynog-T34949-Ab-2 | Anti-Cynomolgus/ Rhesus macaque CACNA1A monoclonal antibody | Cynomolgus/ Rhesus macaque |
GM-Tg-felg-T34949-Ab-1/ GM-Tg-felg-T34949-Ab-2 | Anti-Feline CACNA1A monoclonal antibody | Feline |
GM-Tg-cang-T34949-Ab-1/ GM-Tg-cang-T34949-Ab-2 | Anti-Canine CACNA1A monoclonal antibody | Canine |
GM-Tg-bovg-T34949-Ab-1/ GM-Tg-bovg-T34949-Ab-2 | Anti-Bovine CACNA1A monoclonal antibody | Bovine |
GM-Tg-equg-T34949-Ab-1/ GM-Tg-equg-T34949-Ab-2 | Anti-Equine CACNA1A monoclonal antibody | Equine |
Size: 1mg | 10mg | 100mg
Product Description
Catalog No. | GM-Tg-hg-T34949-Ab-1/ GM-Tg-hg-T34949-Ab-2; GM-Tg-rg-T34949-Ab-1/ GM-Tg-rg-T34949-Ab-2; GM-Tg-mg-T34949-Ab-1/ GM-Tg-mg-T34949-Ab-2; GM-Tg-cynog-T34949-Ab-1/ GM-Tg-cynog-T34949-Ab-2; GM-Tg-felg-T34949-Ab-1/ GM-Tg-felg-T34949-Ab-2; GM-Tg-cang-T34949-Ab-1/ GM-Tg-cang-T34949-Ab-2; GM-Tg-bovg-T34949-Ab-1/ GM-Tg-bovg-T34949-Ab-2; GM-Tg-equg-T34949-Ab-1/ GM-Tg-equg-T34949-Ab-2 |
Products Name | Anti-CACNA1A monoclonal antibody |
Format | mab |
Target Name | CACNA1A |
Protein Sub-location | Transmembrane Protein |
Category of antibody | FACS/Biofunctional Antibody, Therapeutics Target antibody |
Derivation (species) | Mouse |
CH1+2+3 Isotype (Receptor identification) | IgG |
Type of Light Chain (VD-LC) | N/A |
Expression platform | Mammalian Expression |
Bioactivity validation | Binding affinity is validated by using flow cytometry with antigen overexpressed cell line. The biofunction of antibodies are validated in cell-based assay (IC50 or EC50 TBD). |
Tag | Fc |
Products description | Pre-made anti-CACNA1A benchmark inhibitory monoclonal antibody(mab) (blocking antibody inhibitor) is expressed by mammalian cell line as a benchmark antibody for cell culture, FACS,ELISA or other affinity binding assay or functional assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) |
Purity | Purity: ≥95% (SDS-PAGE) |
Application | Biological drug disovery including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research. |
Formulation | Lyophilized from sterile PBS, PH 7.4 |
Storage | Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles. |
Reference
Data / case study
Click to get more Data / Case study about the product.
Associated products
Category | Cat No. | Products Name |
Target Antigen | Products Developing | Multi-species CAC1A/ CACNA1A/ APCA VLP (virus-like particle) (Products Developing) |
Target information
Target ID | GM-T34949 |
Target Name | CACNA1A |
Gene ID | 773,12286,25398,718291,100686650,101094827,282648,100063873 |
Gene Symbol and Synonyms | alpha1A,APCA,BccA1,BI,Caca1a,CACNA1A,CACNL1A4,CAV2.1,Ccha1a,DEE42,EA2,EIEE42,FHM,HPCA,la,MHP,MHP1,nmf352,rbA-1,rkr,SCA6,smrl,tg |
Uniprot Accession | O00555,P54282 |
Uniprot Entry Name | CAC1A_HUMAN,CAC1A_RAT |
Protein Sub-location | Transmembrane Protein |
Category | Therapeutics Target |
Disease | N/A |
Gene Ensembl | ENSG00000141837 |
Target Classification | N/A |
The target: CACNA1A, gene name: CACNA1A, also named as APCA, BI, CACNL1A4, CAV2.1, EA2, EIEE42, FHM, HPCA, MHP, MHP1, SCA6. Voltage-dependent calcium channels mediate the entry of calcium ions into excitable cells, and are also involved in a variety of calcium-dependent processes, including muscle contraction, hormone or neurotransmitter release, and gene expression. Calcium channels are multisubunit complexes composed of alpha-1, beta, alpha-2/delta, and gamma subunits. The channel activity is directed by the pore-forming alpha-1 subunit, whereas, the others act as auxiliary subunits regulating this activity. The distinctive properties of the calcium channel types are related primarily to the expression of a variety of alpha-1 isoforms, alpha-1A, B, C, D, E, and S. This gene encodes the alpha-1A subunit, which is predominantly expressed in neuronal tissue. Mutations in this gene are associated with 2 neurologic disorders, familial hemiplegic migraine and episodic ataxia 2. This gene also exhibits polymorphic variation due to (CAG)n-repeats. Multiple transcript variants encoding different isoforms have been found for this gene. In one set of transcript variants, the (CAG)n-repeats occur in the 3' UTR, and are not associated with any disease. But in another set of variants, an insertion extends the coding region to include the (CAG)n-repeats which encode a polyglutamine tract. Expansion of the (CAG)n-repeats from the normal 4-18 to 21-33 in the coding region is associated with spinocerebellar ataxia 6. [provided by RefSeq, Jul 2016].
About Gmab
GMab, developed by GeneMedi, constitutes an advanced library of recombinant monoclonal antibodies, each meticulously designed to target specific molecular entities. Leveraging the sophisticated capabilities of GM’s Taurus™ and LIBRA™ platforms, GMab synthesizes antibodies characterized by high binding affinity, exceptional physicochemical stability, and optimal developability profiles.
Through expression in mammalian cell lines, GMab has been established as a paradigmatic reference antibody. It holds significance in myriad domains of biological drug discovery, encompassing cellular cultivation, innovative assay methodologies, strategic animal model systematization, in-depth pharmacokinetic & pharmacodynamic (PK/PD) modeling, and intricate mechanism of action (MOA) investigations.